Hexagon Bio
Hexagon Bio is a biopharmaceutical company that discovers and develops small-molecule cytotoxic payloads for antibody-drug conjugates (ADCs) and other therapeutics by mining microbial and metagenomic sequence data. The company combines machine learning, genomics, synthetic biology, chemistry, and automation to build a proprietary microbial genome database and advance discovery candidates through preclinical development toward IND-enabling studies and first-in-human trials, with an initial focus on oncology and infectious disease.
Industries
Nr. of Employees
medium (51-250)
Products
HER2-targeting ADC candidate with translation-inhibitor payload (preclinical)
A HER2-directed antibody-drug conjugate candidate that uses a novel translation-inhibitor small-molecule payload discovered from microbial genomes; advanced through preclinical efficacy, PK, and toxicology studies and undergoing IND-enabling work.
HER2-targeting ADC candidate with translation-inhibitor payload (preclinical)
A HER2-directed antibody-drug conjugate candidate that uses a novel translation-inhibitor small-molecule payload discovered from microbial genomes; advanced through preclinical efficacy, PK, and toxicology studies and undergoing IND-enabling work.
Services
Collaborative discovery and development arrangements to apply the company's platform and proprietary microbial genome resources to partner targets or programs.
Collaborative discovery and development arrangements to apply the company's platform and proprietary microbial genome resources to partner targets or programs.
Expertise Areas
- Natural-product small-molecule discovery
- Antibody-drug conjugate (ADC) payload discovery
- Computational genomics and machine learning
- Synthetic biology and heterologous expression
Key Technologies
- Metagenomic sequencing
- Machine learning for compound discovery
- Bioinformatics for genome-to-compound linking
- Synthetic biology and heterologous expression systems
News & Updates
Company announced formation of a clinical advisory board of breast cancer experts to advise advancement of a HER2-targeting ADC payload candidate toward clinic.
Raised $77.3 million Series B to expand a computational discovery platform and advance microbial genome-derived small molecules; funds to grow interdisciplinary team and platform capabilities.
Closed $47 million Series A to support genomic sequencing of fungi and building a proprietary genomics database for drug discovery.
Reported $61 million financing round to advance small-molecule medicines mined from microbial genomes.
Presented preclinical efficacy and safety data for a translation-inhibitor ADC payload candidate at AACR Annual Meeting 2026, including potency across large cell line panels and favorable PK/toxicity profiles in preclinical species.
Company announced formation of a clinical advisory board of breast cancer experts to advise advancement of a HER2-targeting ADC payload candidate toward clinic.
Raised $77.3 million Series B to expand a computational discovery platform and advance microbial genome-derived small molecules; funds to grow interdisciplinary team and platform capabilities.
Closed $47 million Series A to support genomic sequencing of fungi and building a proprietary genomics database for drug discovery.
Reported $61 million financing round to advance small-molecule medicines mined from microbial genomes.
Presented preclinical efficacy and safety data for a translation-inhibitor ADC payload candidate at AACR Annual Meeting 2026, including potency across large cell line panels and favorable PK/toxicity profiles in preclinical species.